瑞银：首予再鼎医药(09688)“买入”评级近期具明确催化剂但被低估

智通财经10-27

智通财经APP获悉，瑞银发布研报称，基于现金流折现法(DCF)，对再鼎医药(09688)目标价为33.5港元，分别意味着1倍、1.6倍未调整/调整后价格对高峰销售。瑞银认为，市场似乎忽略了再鼎医药的短期增长潜力，包括VYVGART及新产品推出，以及DLL3ADC及ZL-1503(IL-13/IL-31R)等产品的业务发展潜力。瑞银预期，集团核心产品VYVGART将持续扩展适应症并提升销售额，同时...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2578699178?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-27 13:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578699178","market":"fut","top_or_hot":-1,"title":"瑞银：首予再鼎医药(09688)“买入”评级 近期具明确催化剂但被低估","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，瑞银发布研报称，基于现金流折现法(DCF)，对再鼎医药(09688)目标价为33.5港元，分别意味着1倍、1.6倍未调整/调整后价格对高峰销售。瑞银认为，市场似乎忽略了再鼎医药的短期增长潜力，包括VYVGART及新产品推出，以及DLL3ADC及ZL-1503(IL-13/IL-31R)等产品的业务发展潜力。瑞银预期，集团核心产品VYVGART将持续扩展适应症并提升销售额，同时...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1360249.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>瑞银：首予再鼎医药(09688)“买入”评级 近期具明确催化剂但被低估</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n瑞银：首予再鼎医药(09688)“买入”评级 近期具明确催化剂但被低估\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-27 13:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1360249.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，瑞银发布研报称，基于现金流折现法(DCF)，对再鼎医药(09688)目标价为33.5港元，分别意味着1倍、1.6倍未调整/调整后价格对高峰销售。瑞银认为，市场似乎忽略了再鼎医药的短期增长潜力，包括VYVGART及新产品推出，以及DLL3ADC及ZL-1503(IL-13/IL-31R)等产品的业务发展潜力。瑞银预期，集团核心产品VYVGART将持续扩展适应症并提升销售额，同时...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1360249.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZLAB","symbol_name":"再鼎医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1360249.html","article_id":"2578699178","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578699178","pubTimestamp":1761544080,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，瑞银发布研报称，基于现金流折现法，对再鼎医药目标价为33.5港元，分别意味着1倍、1.6倍未调整/调整后价格对高峰销售。瑞银认为，市场似乎忽略了再鼎医药的短期增长潜力，包括VYVGART及新产品推出，以及DLL3ADC及ZL-1503等产品的业务发展潜力。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"ZLAB":"再鼎医药","09688":"再鼎医药"},"translate_title":"UBS: First \"buy\" rating for Zai Lab (09688) has a clear catalyst in the near future but is undervalued","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZLAB":1.5,"09688":1.5},"content_text":"智通财经APP获悉，瑞银发布研报称，基于现金流折现法(DCF)，对再鼎医药(09688)目标价为33.5港元，分别意味着1倍、1.6倍未调整/调整后价格对高峰销售。瑞银认为，市场似乎忽略了再鼎医药的短期增长潜力，包括VYVGART及新产品推出，以及DLL3ADC及ZL-1503(IL-13/IL-31R)等产品的业务发展潜力。瑞银预期，集团核心产品VYVGART将持续扩展适应症并提升销售额，同时预期数个重磅候选药物产品将获批;认为ZL-1310(DLL3ADC)及ZL-1503(IL-13/IL-31R)的业务发展(BD)机会，将为近期增长动力;并相信市场似乎忽略了集团短期增长及业务发展潜力，首次覆盖该股，给予“买入”评级。瑞银相信再鼎医药已商业化的药物VYVGART是同类首创的FcRn药物，并有潜力成为免疫学领域的重磅药物;预测VYVGART在中国的高峰销售额将达到18亿美元。对于产品线候选药物，认为潜在重磅药物可能包括：用于胃癌的Bemarituzumab(FGFR2b)、用于自身免疫疾病的Povetacicept(BAFF/APRIL)、新授权引进的候选药物VRDN-003(IGF-1R)用于甲状腺眼病，以及用于思觉失调的KarXT。瑞银相信，再鼎医药透过收入增长及营运效率改善，将在近期实现盈利，公司亦指引预计2025第四季度实现非公认会计准则(non-GAAP)营运收支平衡，以及2026年全年非公认会计准则营运收支平衡。就毛利率而言，瑞银认为本地制造、VYVGART因产能扩张而降低的销货成本，以及潜在全球产品推出，将改善综合毛利率。就开支而言，公司指引透过优先高价值项目，限制研发开支增长，而销售、一般及行政开支的增长温和。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2578699178","isCrawlerRequest":true}

瑞银：首予再鼎医药(09688)“买入”评级 近期具明确催化剂但被低估

精彩评论

瑞银：首予再鼎医药(09688)“买入”评级近期具明确催化剂但被低估